KV Adds Sherman Act Counterclaims To Ritalin Suit

Law360, New York (December 5, 2008, 12:00 AM EST) -- Generics manufacturer KV Pharmaceutical Company has accused Novartis Pharmaceutials Corp. and Celgene Corp. of violating the Sherman Act in new counterclaims to the drug giants' infringement suit over two patents for blockbuster attention deficit disorder treatment Ritalin LA.

The counterclaims, filed Thursday in the U.S. District Court for the District of New Jersey, also greatly expand upon KV's previous allegations that the two patents are invalid and unenforceable, detailing the generics maker's claims of misconduct before the U.S. Patent and Trademark Office during the prosecution of...
To view the full article, register now.